ETFs Holding CDTX »    CDTX Historical Stock Prices »
CDTX News Video: Mon, Apr 15, 2019, 1:33 PM — Monday Sector Laggards: Biotechnology, Drugs

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of anti-infectives for the treatment of diseases. Co.'s primary product candidate is rezafungin acetate, an intravenous formulation of an echinocandin, which is being developed as a therapy for the treatment and prevention of fungal infections. In addition, Co. is developing its antibody-drug conjugates for multidrug-resistant bacterial infections as part of its proprietary Cloudbreak™ platform, which is designed to discover compounds that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal or viral pathogens. Self directed investors in Cidara Therapeutics Inc will be interested in keeping up with all Cidara Therapeutics Inc news they can find, both CDTX news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on CDTX. At RediNews, we simplify this task by presenting both CDTX news releases originating from Cidara Therapeutics Inc itself, and CDTX news from a variety of media outlets. Visitors can browse this news online and through our CDTX RSS news feed.


CDTX News — Articles, Videos, & Press Releases

Implied ITOT Analyst Target Price: $72
Wednesday, May 8, 2019, 8:08 AM — ETF Channel
Analysts Expect IWC To Hit $120
Thursday, April 4, 2019, 8:22 AM — ETF Channel
Look Under The Hood: IWC Has 26% Upside
Thursday, February 28, 2019, 8:08 AM — ETF Channel
Analysts Expect RYJ Will Reach $56
Monday, January 21, 2019, 8:40 AM — ETF Channel
Analysts See 46% Upside For RYJ
Wednesday, December 12, 2018, 8:08 AM — ETF Channel
The Math Shows RYJ Can Go To $59
Thursday, November 8, 2018, 8:25 AM — ETF Channel
Look Under The Hood: RYJ Has 24% Upside
Friday, October 5, 2018, 7:57 AM — ETF Channel
Implied RYJ Analyst Target Price: $58
Friday, August 24, 2018, 9:30 AM — ETF Channel
Oversold Conditions For Cidara Therapeutics (CDTX)
Thursday, July 19, 2018, 4:24 PM — Dividend Channel
Implied RYJ Analyst Target Price: $57
Tuesday, July 3, 2018, 8:04 AM — ETF Channel
Analysts Expect SPTM Will Reach $38
Thursday, May 31, 2018, 8:23 AM — ETF Channel
CDTX is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

GI News

RediNews invites financial news content websites to integrate our XML content for web sites by integrating our RSS feeds found throughout our website wherever news and stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic content is ideal for any financial portal or web portal, from business content web sites to corporate portal intranets. Let RediNews be your content provider of free financial content for news, perfect for location on stock market chart pages by symbol, adding another element of dynamic stock market content to your financial portal. If your web page content already includes elements like SEC filings, screener pages, historical chart information, and other cobranded financial web content, then headlines from RediNews can supplement this dynamic financial content meaningfully.

CDTX News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.